CRDF Q2 2025 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$121,000-25.8% YoY

Gross Profit

-$11M-9470.2% margin

Operating Income

-$15M-12212.4% margin

Net Income

-$14M-11523.1% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+11.0%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$76M

Total Liabilities

$17M

Stockholders' Equity

$59M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$121,000	$163,000	-25.8%
Gross Profit	-$11M	$58,000	-19856.9%
Operating Income	-$15M	-$13M	-17.8%
Net Income	-$14M	-$12M	-18.4%